Everything COVID...
US Pandemic Emergency ends May 11th, 2023
Mandates, Quarantine, Passports, Discrimination, Boosters, Tests, Protests, Censorship, Lockdowns, Masks, Fines, Incentives and Lawsuits
CDC COVID data tracker...
May 2, 2023- by Steven E. Greer, MD A new medical meeting poster shows the results of a double blind, randomized, controlled trial of ivermectin as a therapy for COVID. The drug works very well. MedinCell is the drug company that conducted the trial. They are making a long-acting version of ivermectin to sell at higher prices than the generic version.
Federal Government Drops COVID-19 Vaccine Travel Mandate on Same Day It Was Due to Respond to ICAN’s Legal Challenge... On April 4, 2023, ICAN’s attorneys filed a lawsuit challenging the Travel Ban, which prohibits non-citizens from entering the United States without a COVID-19 vaccine. ICAN is thrilled to announce that today, the same day that the Government’s response to the motion for an injunction in that lawsuit was due, the Biden Administration announced it was ending the Travel Ban’s vaccination mandate.
Texas to Investigate COVID Vaccine Makers Over Gain-of-Function Research, False Efficacy Claims... Texas Attorney General Ken Paxton today launched an investigation into whether Pfizer, Moderna and Johnson & Johnson committed fraud related to the COVID-19 vaccines. Paxton will investigate whether the companies misrepresented the efficacy and safety of the vaccines and manipulated vaccine trial data, in violation of the state’s Deceptive Trade Practices Act. He also will investigate whether the pharmaceutical giants engaged in gain-of-function research and misled the public about it, The New York Post reported.
Quercetin for COVID-19: real-time meta analysis of 10 studies... Quercetin reduces risk for COVID-19 with very high confidence for recovery, cases, viral clearance, and in pooled analysis, high confidence for ICU admission, low confidence for hospitalization, and very low confidence for mortality. Studies typically use advanced formulations for greatly improved bioavailability. We show traditional outcome specific analyses and combined evidence from all studies, incorporating treatment delay, a primary confounding factor in COVID-19 studies. Real-time updates and corrections, transparent analysis with all results in the same format, consistent protocol for 51 treatments.
Healing from the Spike Protein
Ivermectin works against COVID in double blind, randomized, controlled trial... May 2, 2023- by Steven E. Greer, MD A new medical meeting poster shows the results of a double blind, randomized, controlled trial of ivermectin as a therapy for COVID. The drug works very well. MedinCell is the drug company that conducted the trial. They are making a long-acting version of ivermectin to sell at higher prices than the generic version.
Spike Protein Detox Guide... This is an evolving guide with emerging information on how to clear viral and vaccine-induced spike proteins from the body. The lists of herbal and other medicines and supplements have been compiled in a collaboration between international doctors, scientists, and holistic medical practitioners.
New Information from Japan Finds That Nattokinase Degrades or Dissolves the Harmful Spike Protein. It's also a natural anti-fibrinolytic agent for blood clots. Nattokinase is featured in @twc_health's formula for those concerned about spike proteins.
Degradative Effect of Nattokinase on Spike Protein of SARS-CoV-2... The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged as a pandemic and has inflicted enormous damage on the lives of the people and economy of many countries worldwide. However, therapeutic agents against SARS-CoV-2 remain unclear. SARS-CoV-2 has a spike protein (S protein), and cleavage of the S protein is essential for viral entry. Nattokinase is produced by Bacillus subtilis var. natto and is beneficial to human health. In this study, we examined the effect of nattokinase on the S protein of SARS-CoV-2. When cell lysates transfected with S protein were incubated with nattokinase, the S protein was degraded in a dose- and time-dependent manner. Immunofluorescence analysis showed that S protein on the cell surface was degraded when nattokinase was added to the culture medium. Thus, our findings suggest that nattokinase exhibits potential for the inhibition of SARS-CoV-2 infection via S protein degradation.
